Online inquiry

IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13927MR)

This product GTTS-WQ13927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Fibrodysplasia ossificans prograssiva (FOP) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ13927MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4741MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ11390MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ7535MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ15046MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ15691MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ7210MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ14061MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ6715MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS 1024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW